A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
Status: Recruiting
Location: See all (40) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• See Master Protocol CWMM (NCT06143956) for inclusion criteria
Locations
United States
Arizona
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
RECRUITING
Chandler
Headlands Research - Scottsdale
RECRUITING
Scottsdale
The Institute for Liver Health II dba Arizona Liver Health-Tucson
RECRUITING
Tucson
California
NorCal Medical Research, Inc
RECRUITING
Greenbrae
Velocity Clinical Research, Huntington Park
RECRUITING
Huntington Park
Peninsula Research Associates
RECRUITING
Rolling Hills Estates
Diablo Clinical Research, Inc.
RECRUITING
Walnut Creek
Connecticut
Stamford Therapeutics Consortium
RECRUITING
Stamford
Florida
New Horizon Research Center
RECRUITING
Miami
Indago Research & Health Center, Inc
RECRUITING
Miami Lakes
Suncoast Clinical Research, Inc.
RECRUITING
New Port Richey
Charter Research - Winter Park
RECRUITING
Orlando
Charter Research - Lady Lake
RECRUITING
The Villages
Idaho
Medical Research Partners
RECRUITING
Ammon
Illinois
Great Lakes Clinical Trials - Ravenswood
RECRUITING
Chicago
Kansas
Cotton O'Neil Diabetes & Endocrinology
RECRUITING
Topeka
Kentucky
Monroe Biomedical Research - Louisville
RECRUITING
Louisville
Massachusetts
Knownwell
RECRUITING
Needham
Lucida Clinical Trials
RECRUITING
New Bedford
Michigan
Headlands Research - Detroit
RECRUITING
Southfield
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
RECRUITING
Troy
Missouri
StudyMetrix Research
RECRUITING
City Of Saint Peters
Clinvest Headlands Llc
RECRUITING
Springfield
North Carolina
Medication Management
RECRUITING
Greensboro
Monroe Biomedical Research
RECRUITING
Monroe
Lucas Research, Inc
RECRUITING
Morehead City
Lucas Research, Inc.
RECRUITING
New Bern
Nevada
Las Vegas Medical Research
RECRUITING
Las Vegas
New York
Dent Neurologic Institute
RECRUITING
Amherst
Rochester Clinical Research, LLC
RECRUITING
Rochester
Ohio
CTI Clinical Research Center
RECRUITING
Cincinnati
South Carolina
Tribe Clinical Research, LLC
RECRUITING
Greenville
Tennessee
Quality Medical Research
RECRUITING
Nashville
Texas
IMA Clinical Research Austin
RECRUITING
Austin
FutureSearch Trials of Dallas
RECRUITING
Dallas
PlanIt Research, PLLC
RECRUITING
Houston
Endeavor Clinical Trials
RECRUITING
San Antonio
Texas Valley Clinical Research
RECRUITING
Weslaco
Virginia
Sovah Clinical Research-River District
RECRUITING
Danville
Washington
Central Washington Health Services Association d/b/a Confluence Health
RECRUITING
Wenatchee
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2026-05-15
Estimated Completion Date: 2028-02
Participants
Target number of participants: 400
Treatments
Experimental: Macupatide Dose 1
Participants will receive macupatide subcutaneously (SC)
Experimental: Eloralintide Dose 1
Participants will receive eloralintide SC
Experimental: Macupatide Dose 1 + Eloralintide Dose 1
Participants will receive macupatide SC and eloralintide SC
Experimental: Eloralintide Dose 2
Participants will receive eloralintide SC
Experimental: Macupatide Dose 1 + Eloralintide Dose 2
Participants will receive macupatide SC and eloralintide SC
Experimental: Eloralintide Dose 3
Participants will receive eloralintide SC
Experimental: Macupatide Dose 2 + Eloralintide Dose 3
Participants will receive macupatide SC and eloralintide SC
Placebo_comparator: Placebo
Participants will receive placebo SC
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company